Literature DB >> 17059819

Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy.

J Jarosik1, B Legutko, K Unsicker, O von Bohlen Und Halbach.   

Abstract

Olfactory bulbectomy is an established animal model of depression that has been mostly investigated in rats. As in human major depression, bulbectomy induces behavioral alterations that can be ameliorated by chronic antidepressant treatment. Furthermore, bulbectomy in rats is known to induce neurodegeneration in some brain areas. The aim of the present study was to evaluate patterns of behavioral alterations and neurodegeneration, and their drug-induced reversibility, in bulbectomized mice. Our results reveal that in mice bulbectomy increases locomotor activity and induces deficits in the passive avoidance test, comparable to the effects seen in rats. Bulbectomy also induced neuronal degeneration, visualized by incorporation of Fluoro-Jade B, in the piriform cortex and the posterolateral cortical amygdaloid nucleus (PLCo). Chronic treatment with the antidepressant amitriptyline protected neurons in both areas and efficiently reversed abnormal locomotor activity induced by bulbectomy. Treatment with citalopram was effective in reversing the behavioral deficits induced by bulbectomy, but did not protect against neurodegeneration. Our data indicate significant overlap between mice and rats in terms of behavioral alterations and neurodegeneration following olfactory bulbectomy. However, there are differences in drug-mediated reversibility of neurodegeneration suggesting that neurodegeneration and protection may be "second-order" features in this animal model of depression. This may also be relevant in the context of studies using genetically altered mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059819     DOI: 10.1016/j.expneurol.2006.09.008

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  18 in total

1.  Forced swimming stress does not affect monoamine levels and neurodegeneration in rats.

Authors:  Ghulam Abbas; Sabira Naqvi; Shahab Mehmood; Nurul Kabir; Ahsana Dar
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

2.  Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Shvetank Bhatt
Journal:  Psychopharmacology (Berl)       Date:  2014-08-15       Impact factor: 4.530

3.  Deep brain stimulation in rats: different targets induce similar antidepressant-like effects but influence different circuits.

Authors:  Clement Hamani; Beatriz O Amorim; Anne L Wheeler; Mustansir Diwan; Klaus Driesslein; Luciene Covolan; Christopher R Butson; José N Nobrega
Journal:  Neurobiol Dis       Date:  2014-08-13       Impact factor: 5.996

4.  Diet-induced obesity resistance of Kv1.3-/- mice is olfactory bulb dependent.

Authors:  K Tucker; J M Overton; D A Fadool
Journal:  J Neuroendocrinol       Date:  2012-08       Impact factor: 3.627

Review 5.  Molecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: a Review.

Authors:  Marcos Roberto de Oliveira; Aline Lukasievicz Chenet; Adriane Ribeiro Duarte; Giselli Scaini; João Quevedo
Journal:  Mol Neurobiol       Date:  2017-07-10       Impact factor: 5.590

6.  Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment.

Authors:  Steven J Shabel; Christophe D Proulx; Joaquin Piriz; Roberto Malinow
Journal:  Science       Date:  2014-09-18       Impact factor: 47.728

7.  Correlation of depressive symptoms and olfactory dysfunction in patients on hemodialysis.

Authors:  E Grapsa; E Samouilidou; K Pandelias; C Pipili; N Papaioannou; T Mpakirzi; H Tzanatos
Journal:  Hippokratia       Date:  2010-07       Impact factor: 0.471

Review 8.  Neuroinflammation, neurodegeneration, and depression.

Authors:  Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2012-08-16       Impact factor: 3.911

9.  SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

Authors:  M E Breuer; M M van Gaalen; W Wernet; S E F Claessens; R S Oosting; B Behl; S M Korte; H Schoemaker; G Gross; B Olivier; L Groenink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-31       Impact factor: 3.000

Review 10.  Analysis of morphological changes as a key method in studying psychiatric animal models.

Authors:  Oliver von Bohlen und Halbach
Journal:  Cell Tissue Res       Date:  2013-01-20       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.